US75382E1091 - Common Stock
RAPT THERAPEUTICS INC
NASDAQ:RAPT (5/6/2024, 7:23:53 PM)
After market: 8.28 0 (0%)8.28
-0.05 (-0.6%)
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 129 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues. Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. In addition, RPT193 has clinical translatability in a variety of inflammatory diseases beyond atopic dermatitis (AD), including allergic asthma and chronic rhinosinusitis.
RAPT THERAPEUTICS INC
561 Eccles Ave
South San Francisco CALIFORNIA 94080
P: 16504899000
CEO: Brian Wong
Employees: 129
Website: https://rapt.com/
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with...
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Here you can normally see the latest stock twits on RAPT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: